mFOLFOXIRI + bevacizumab

mFOLFOXIRI + bevacizumab is a combination chemotherapy regimen used primarily for the treatment of metastatic colorectal cancer. The regimen consists of four cytotoxic agents—oxaliplatin, irinotecan, 5-fluorouracil (5-FU), and folinic acid (leucovorin)—administered in a modified dosing schedule, together with the monoclonal antibody bevacizumab. The mechanism of action involves multiple pathways: - Oxaliplatin is a platinum-based chemotherapeutic that forms DNA crosslinks and inhibits DNA synthesis. - Irinotecan inhibits topoisomerase I, preventing DNA replication. - 5-Fluorouracil is an antimetabolite that interferes with thymidylate synthase and RNA function. - Folinic acid enhances the binding of 5-FU to its target enzyme, increasing efficacy. Bevacizumab targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth[1][5]. This combination has demonstrated improved progression-free survival in first-line and salvage settings for metastatic colorectal cancer[1][3][5].

Other names

modified FOLFOXIRI plus bevacizumabmFOLFOXIRI/BevFOLFOXIRI (modified) plus bevacizumab